FCS is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma (RRMM). The treatment, teclistamab (TECVAYLI®), is a type of rapidly evolving cancer therapy that uses the body’s immune system to fight cancer.
Pharmacy experts and leaders from Florida Cancer Specialists & Research Institute, LLC (FCS) are contributing to improving cancer care globally as they join fellow oncology professionals for the NCODA 2023 International Fall Summit in Orlando this week.
Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
FCS clinicians and senior leaders are among the industry experts who will present breakthrough data, research and clinical strategies at the Florida Society of Clinical Oncology (FLASCO) Fall Session in Orlando this month.
Executive leaders of Florida Cancer Specialists & Research Institute (FCS) will serve on the faculty for the Association for Value-Based Cancer Care 2023 Summit & Educational Program in New York, NY on Oct. 18 – 20.
A best practice clinical program developed by FCS is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.
Bispecific Treatment For Multiple Myeloma Now Available In Sarasota CountyFCS is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma (RRMM). The treatment, teclistamab (TECVAYLI®), is a type of rapidly evolving cancer therapy that uses the body’s immune system to fight cancer.
FCS leaders present at NCODA 2023 Fall SummitPharmacy experts and leaders from Florida Cancer Specialists & Research Institute, LLC (FCS) are contributing to improving cancer care globally as they join fellow oncology professionals for the NCODA 2023 International Fall Summit in Orlando this week.
FCS physicians present findings at ESMO 2023Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
Leaders and physicians from FCS will participate in the 2023 FLASCO Fall SessionFCS clinicians and senior leaders are among the industry experts who will present breakthrough data, research and clinical strategies at the Florida Society of Clinical Oncology (FLASCO) Fall Session in Orlando this month.
Executive leaders from FCS discuss industry-leading approach to value-based care at AVBCC Summit 2023Executive leaders of Florida Cancer Specialists & Research Institute (FCS) will serve on the faculty for the Association for Value-Based Cancer Care 2023 Summit & Educational Program in New York, NY on Oct. 18 – 20.
FCS Optimizing Use of Anticancer Drugs to Improve Care for Patients with Blood DisordersA best practice clinical program developed by FCS is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.
Hypofractionation Radiotherapy For Prostate CancerHypofractionated radiotherapy shortens the overall duration of radiation therapy for prostate cancer patients.
Prostate Cancer 101Does a vasectomy increase risk of prostate cancer? Learn what causes prostate cancer, where it is located and 5 warning signs to look for.